Kiniksa Pharmaceuticals International, plc

NasdaqGS:KNSA Stock Report

Market Cap: US$1.5b

Kiniksa Pharmaceuticals International Past Earnings Performance

Past criteria checks 0/6

Kiniksa Pharmaceuticals International has been growing earnings at an average annual rate of 45.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 65.2% per year.

Key information

45.9%

Earnings growth rate

48.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate65.2%
Return on equity-2.1%
Net Margin-2.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story

Oct 07

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 07
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Jul 24

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Jun 19
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Apr 25
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Apr 24

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Revenue & Expenses Breakdown

How Kiniksa Pharmaceuticals International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:KNSA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24384-916496
30 Jun 24339-1015288
31 Mar 24302913987
31 Dec 232701412976
30 Sep 23249-712070
30 Jun 2328123111070
31 Mar 2323619610560
31 Dec 222201839865
30 Sep 221771439379
30 Jun 2290-1129081
31 Mar 2271-1348891
31 Dec 2139-1588699
30 Sep 2120-17579109
30 Jun 218-18970121
31 Mar 210-18457120
31 Dec 200-16145112
30 Sep 200-1403899
30 Jun 200-1233589
31 Mar 200-1223597
31 Dec 190-16235135
30 Sep 190-17335147
30 Jun 190-17031146
31 Mar 190-15327133
31 Dec 180-1032287
30 Sep 180-931680
30 Jun 180-851374
31 Mar 180-761165
31 Dec 170-65956

Quality Earnings: KNSA is currently unprofitable.

Growing Profit Margin: KNSA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KNSA is unprofitable, but has reduced losses over the past 5 years at a rate of 45.9% per year.

Accelerating Growth: Unable to compare KNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: KNSA has a negative Return on Equity (-2.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kiniksa Pharmaceuticals International, plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Liisa BaykoEvercore ISI
Paul ChoiGoldman Sachs